Advances in Pancreatic Ductal Adenocarcinoma Diagnosis and Treatment 2nd Edition

Dear Colleagues,

Pancreatic cancer therapy is progressing slowly but step by step. Surgery remains a potentially curative treatment for pancreatic ductal adenocarcinoma (PDAC) without metastases, and en bloc resection with adequate surgical margins is associated with long-term survival. Venous invasion does not preclude patients from surgery because combined venous resection and reconstitution can be safely performed. Resection and reconstitution of the affected arteries without a significant increase in mortality have been recently reported. Despite advanced surgery, most patients will develop metastatic disease, and there is therefore a great deal of debate about how to improve patient survival by using neoadjuvant or adjuvant chemotherapy with or without radiation therapy. Optimal supportive management, in particular nutritional treatment and care for PDAC patients in order to achieve a good quality of life, currently plays an increasingly important role. In the age of molecularly targeted drugs and immunotherapy, researchers take great efforts to find the best targeted therapy based on the genomics and proteomics of PDAC. Using our many years of experience in the treatment of patients with PDAC and taking into account the latest scientific achievements, this Special Issue will discuss recent developments in understanding genomic characteristics, early-detection approaches, and innovations in the treatment of resectable, borderline resectable, locally advanced, and metastatic PDAC, as well as recent developments in the application of therapeutics targeting new targets in pancreatic carcinoma.

Prof. Dr. Andrzej Deptała
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.